Are you ready? EU’s Clinical Trials Regulation and portal goes live 31 January
The EU’s Clinical Trials Regulation and information system aims to streamline applications and bolster transparency – but initial rollout could face growing pains.
By
William Newton
William Newton is a reporter for Clinical Trials Arena and Pharmaceutical Technology, focusing on rare diseases, Covid-19 antivirals, and the central nervous system. Now based in New York City, he previously covered diabetes drug development at Close Concerns’ industry-facing publication in San Francisco. William holds a BA in Economics from Williams College.
Latest articles
All Articles
Pipeline Moves: GSK’s likelihood of further study in tuberculosis rises
Stuart Therapeutics in dry eye disease and Vifor Pharma in beta thalassemia are also reviewed by Clinical Trials Arena.
By
ALS: drug trial results to watch in 2022
Pharma companies are pouring more efforts into ALS studies, setting the stage for several major drug trial readouts this…
By
Regulatory roundup: Albireo ASBT inhibitor shot at further study rises in liver diseases
Roche in ulcerative colitis and Alzamend Neuro in dementia associated with Alzheimer’s disease are also reviewed by GlobalData’s Investigative…
By
Basket and umbrella trials: untapped opportunities in rare disease
Basket trials have more traction than umbrella trials, but both are a drop in the bucket in total rare…
By
Medicago previews VLP Covid-19 vaccine booster trial slated for January
In an exclusive, Medicago reveals its booster trial plans, including a tweaked vaccine with similar mutations to the Omicron…
By
Platform trials: an opportunity for rare dystrophies or gene therapies?
Platform trials offer a streamlined approach to rare disease research, but regulatory and design obstacles loom large.
By
Annovis reveals blueprint for Phase III Alzheimer’s, Parkinson’s disease trials
Annovis CEO Maria Maccecchini shares recruitment approaches and endpoint choices for late-phase tests.
By
Iterion to begin Phase I tegavivint trial in lung cancer later this year
The planned Phase I trial will test tegavivint with Tagrisso in EGFR-positive non-small cell lung cancer patients.
By